Literature DB >> 25567323

Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model.

Carla Martins1, Helena Hůlková2, Larbi Dridi1, Virginie Dormoy-Raclet1, Lubov Grigoryeva1, Yoo Choi1, Alexander Langford-Smith3, Fiona L Wilkinson3, Kazuhiro Ohmi4, Graziella DiCristo1, Edith Hamel5, Jerôme Ausseil6, David Cheillan7, Alain Moreau1, Eva Svobodová2, Zuzana Hájková8, Markéta Tesařová8, Hana Hansíková8, Brian W Bigger3, Martin Hrebícek2, Alexey V Pshezhetsky9.   

Abstract

Severe progressive neurological paediatric disease mucopolysaccharidosis III type C is caused by mutations in the HGSNAT gene leading to deficiency of acetyl-CoA: α-glucosaminide N-acetyltransferase involved in the lysosomal catabolism of heparan sulphate. To understand the pathophysiology of the disease we generated a mouse model of mucopolysaccharidosis III type C by germline inactivation of the Hgsnat gene. At 6-8 months mice showed hyperactivity, and reduced anxiety. Cognitive memory decline was detected at 10 months and at 12-13 months mice showed signs of unbalanced hesitant walk and urinary retention. Lysosomal accumulation of heparan sulphate was observed in hepatocytes, splenic sinus endothelium, cerebral microglia, liver Kupffer cells, fibroblasts and pericytes. Starting from 5 months, brain neurons showed enlarged, structurally abnormal mitochondria, impaired mitochondrial energy metabolism, and storage of densely packed autofluorescent material, gangliosides, lysozyme, phosphorylated tau, and amyloid-β. Taken together, our data demonstrate for the first time that deficiency of acetyl-CoA: α-glucosaminide N-acetyltransferase causes lysosomal accumulation of heparan sulphate in microglial cells followed by their activation and cytokine release. They also show mitochondrial dysfunction in the neurons and neuronal loss explaining why mucopolysaccharidosis III type C manifests primarily as a neurodegenerative disease.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  acetyl-CoA: α-glucosaminide N-acetyltransferase; glycosaminoglycans; heparan sulphate; knockout mouse model; mucopolysaccharidosis

Mesh:

Substances:

Year:  2015        PMID: 25567323      PMCID: PMC4306821          DOI: 10.1093/brain/awu355

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  57 in total

1.  Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway.

Authors:  P Bifsha; K Landry; L Ashmarina; S Durand; V Seyrantepe; S Trudel; C Quiniou; S Chemtob; Y Xu; R A Gravel; R Sladek; A V Pshezhetsky
Journal:  Cell Death Differ       Date:  2006-08-04       Impact factor: 15.828

2.  Sanfilippo syndrome type C: deficiency of acetyl-CoA:alpha-glucosaminide N-acetyltransferase in skin fibroblasts.

Authors:  U Klein; H Kresse; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

3.  Analysis of the biogenesis of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase provides insights into the mechanism underlying its complete deficiency in mucopolysaccharidosis IIIC.

Authors:  Stéphanie Durand; Matthew Feldhammer; Eric Bonneil; Pierre Thibault; Alexey V Pshezhetsky
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

4.  Evaluation of dexamethasone for the treatment of intracerebral hemorrhage using a collagenase-induced intracerebral hematoma model in rats.

Authors:  P P Lema; C Girard; P Vachon
Journal:  J Vet Pharmacol Ther       Date:  2004-10       Impact factor: 1.786

5.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

6.  Innate and adaptive immune activation in the brain of MPS IIIB mouse model.

Authors:  Julianne DiRosario; Erin Divers; Chuansong Wang; Jonathan Etter; Alyssa Charrier; Peter Jukkola; Herbert Auer; Victoria Best; David L Newsom; Douglas M McCarty; Haiyan Fu
Journal:  J Neurosci Res       Date:  2009-03       Impact factor: 4.164

7.  Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.

Authors:  G J G Ruijter; M J Valstar; J M van de Kamp; R M van der Helm; S Durand; O P van Diggelen; R A Wevers; B J Poorthuis; A V Pshezhetsky; F A Wijburg
Journal:  Mol Genet Metab       Date:  2007-11-19       Impact factor: 4.797

8.  Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention.

Authors:  Brian P Zambrowicz; Alejandro Abuin; Ramiro Ramirez-Solis; Lizabeth J Richter; James Piggott; Hector BeltrandelRio; Eric C Buxton; Joel Edwards; Rick A Finch; Carl J Friddle; Anupma Gupta; Gwenn Hansen; Yi Hu; Wenhu Huang; Crystal Jaing; Billie Wayne Key; Peter Kipp; Buckley Kohlhauff; Zhi-Qing Ma; Diane Markesich; Robert Payne; David G Potter; Ny Qian; Joseph Shaw; Jeff Schrick; Zheng-Zheng Shi; Mary Jean Sparks; Isaac Van Sligtenhorst; Peter Vogel; Wade Walke; Nianhua Xu; Qichao Zhu; Christophe Person; Arthur T Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

9.  Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.

Authors:  Fiona L Wilkinson; Rebecca J Holley; Kia J Langford-Smith; Soumya Badrinath; Aiyin Liao; Alex Langford-Smith; Jonathan D Cooper; Simon A Jones; J Ed Wraith; Rob F Wynn; Catherine L R Merry; Brian W Bigger
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

10.  Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice.

Authors:  Jérôme Ausseil; Nathalie Desmaris; Stéphanie Bigou; Ruben Attali; Sébastien Corbineau; Sandrine Vitry; Mathieu Parent; David Cheillan; Maria Fuller; Irène Maire; Marie-Thérèse Vanier; Jean-Michel Heard
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

View more
  49 in total

Review 1.  Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.

Authors:  Afshin Saffari; Stefan Kölker; Georg F Hoffmann; Darius Ebrahimi-Fakhari
Journal:  J Inherit Metab Dis       Date:  2017-05-05       Impact factor: 4.982

2.  Synaptic failure: The achilles tendon of sphingolipidoses.

Authors:  Ludovico Cantuti-Castelvetri; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.

Authors:  Adeline A Lau; Barbara M King; Carly L Thorsen; Sofia Hassiotis; Helen Beard; Paul J Trim; Lauren S Whyte; Sarah J Tamang; Stephen K Duplock; Marten F Snel; John J Hopwood; Kim M Hemsley
Journal:  J Inherit Metab Dis       Date:  2017-04-27       Impact factor: 4.982

4.  Glucosamine amends CNS pathology in mucopolysaccharidosis IIIC mouse expressing misfolded HGSNAT.

Authors:  Xuefang Pan; Mahsa Taherzadeh; Poulomee Bose; Rachel Heon-Roberts; Annie L A Nguyen; TianMeng Xu; Camila Pará; Yojiro Yamanaka; David A Priestman; Frances M Platt; Shaukat Khan; Nidhi Fnu; Shunji Tomatsu; Carlos R Morales; Alexey V Pshezhetsky
Journal:  J Exp Med       Date:  2022-06-15       Impact factor: 17.579

Review 5.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

6.  Behavioral deficits and cholinergic pathway abnormalities in male Sanfilippo B mice.

Authors:  Shih-Hsin Kan; Steven Q Le; Quang D Bui; Braeden Benedict; Jesse Cushman; Mark S Sands; Patricia I Dickson
Journal:  Behav Brain Res       Date:  2016-06-23       Impact factor: 3.332

7.  Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.

Authors:  Haiyan Fu; Aaron S Meadows; Ricardo J Pineda; Robert P Mohney; Steve Stirdivant; Douglas M McCarty
Journal:  Metab Brain Dis       Date:  2017-04-05       Impact factor: 3.584

8.  Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.

Authors:  Alessandra d'Azzo; Eda Machado; Ida Annunziata
Journal:  Expert Opin Orphan Drugs       Date:  2015-04-13       Impact factor: 0.694

9.  Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.

Authors:  Tyler A Harm; Shannon J Hostetter; Ariel S Nenninger; Bethann N Valentine; N Matthew Ellinwood; Jodi D Smith
Journal:  Vet Pathol       Date:  2020-11-18       Impact factor: 2.221

10.  An Engineered sgsh Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA.

Authors:  Alon M Douek; Mitra Amiri Khabooshan; Jason Henry; Sebastian-Alexander Stamatis; Florian Kreuder; Georg Ramm; Minna-Liisa Änkö; Donald Wlodkowic; Jan Kaslin
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.